The global monoclonal antibodies market size was valued at USD 232.72 million in 2024 and is projected to grow from USD 261.44 million in 2025 to reach USD 707.81 million by 2033, exhibiting a CAGR of 13.3% during the forecast period (2025-2033).
Monoclonal antibodies are laboratory-engineered molecules designed to bind specifically to antigens, such as those found on the surface of pathogens or cancer cells. These antibodies are produced by creating identical immune cells cloned from a unique parent cell, allowing for precise targeting of harmful cells while minimizing damage to healthy ones.
Monoclonal antibodies mimic the immune system's natural defense mechanisms and are widely used in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. The rising prevalence of chronic diseases, the increasing use of monoclonal antibodies in oncology, and the growing approval of new monoclonal antibody therapies are significant contributors.
Moreover, the development of bispecific and multi-specific antibodies is advancing the field. Collaborations and partnerships between biotechnology companies and government research institutes further fuel market growth, solidifying the dominance of monoclonal antibodies in the healthcare sector.
Below graph represents the global incidence of cancer in 2022
Source: World Cancer Research Fund and Straits Research
The trend of bispecific and multi-specific antibodies, including tri-specific and tetra-specific variations, is significantly driving market growth. These advanced antibodies represent a breakthrough in therapeutic applications by providing multiple antigen-binding sites, which enable targeting two or more different epitopes simultaneously.
The FDA has approved numerous bispecific antibodies, and over 100 multi-specific antibodies are currently undergoing clinical trials. This multi-targeting capability enhances specificity and effectiveness in treatment.
For example, in October 2023, EpimAb Biotherapeutics and Almirall entered a bispecific antibody license agreement targeting three undisclosed pairs, highlighting the growing industry focus on such innovative therapies.
These advancements in antibody technology are propelling market growth by offering enhanced therapeutic efficiency.
Monoclonal antibodies are increasingly adopted as personalized medicines due to their potential to tailor treatment for various diseases, offering a significant alternative to standard therapies. Their specificity in targeting diseases like cancer, autoimmune disorders, and infectious diseases underscores their role in personalized medicine.
The growing adoption of monoclonal antibodies for personalized medicine is a major driver of market growth, emphasizing their targeted efficiency and potential to transform therapeutic approaches.
The rising number of approvals for new monoclonal antibodies is a significant driver of market growth. Monoclonal antibodies have proven highly effective in treating diseases such as cancer and other chronic conditions, making them increasingly valuable for disease-specific and personalized treatment approaches. This growing efficacy has spurred extensive research and development, leading to more regulatory approvals.
These approvals highlight the expanding role of monoclonal antibodies in modern therapeutics, driving market growth.
The adoption of monoclonal antibodies in cancer treatment is another key market driver. Cancer, a notoriously challenging disease to treat, demands highly targeted and effective therapies. Monoclonal antibodies provide a strong, targeted approach that significantly enhances cancer treatment outcomes.
These developments underscore the growing reliance on monoclonal antibodies in oncology, further propelling market expansion.
Patent expirations pose significant challenges to the growth of the monoclonal antibodies market in several ways. When the patent for a monoclonal antibody expires, it opens the market to biosimilar manufacturers, increasing competition and potentially reducing the market share of the original product. This competition can lead to lower prices, thereby affecting the revenue of original manufacturers.
For example, Stelara, an IgG1 kappa human monoclonal antibody approved in 2016 for treating Crohn’s disease, had its patent protection expire in the U.S. in 2023 and is set to expire in Europe in 2024. The expiration of such patents invites biosimilar competition, challenging market dynamics and growth.
Thus, patent expirations restrain market growth by introducing challenges from biosimilar manufacturers and impacting investment strategies.
The expanding pipeline of monoclonal antibodies, driven by their emerging applications across various diseases, presents significant market opportunities. Monoclonal antibodies are proving highly effective in treating different types of cancers and chronic diseases, and their role in personalized medicine is growing rapidly.
This efficiency and disease specificity are encouraging key players to invest heavily in research and development, leading to a robust pipeline of monoclonal antibodies in clinical trials. As these trials progress and new therapies gain approval, the market stands to benefit from innovative treatments tailored to specific medical needs.
Below table represents the number of monoclonal antibody products in the pipeline of various market players
|
Company Name |
Number of Products in Pipeline |
|
Novartis AG |
4 |
|
Merck & Co., Inc. |
11 |
|
Edisa Biotech, Inc. |
4 |
|
Pfizer Inc. |
2 |
Source: Company Websites & Straits Research
Thus, the presence of multiple products in the pipeline provides the scope for opportunities for overall market growth.
| Study Period | 2021-2033 | CAGR | 13.3% |
| Historical Period | 2021-2023 | Forecast Period | 2025-2033 |
| Base Year | 2024 | Base Year Market Size | USD 232.72 million |
| Forecast Year | 2033 | Forecast Year Market Size | USD 707.81 million |
| Largest Market | North America | Fastest Growing Market | Asia-Pacific |
North America holds the largest revenue share in the monoclonal antibodies industry, driven by a robust healthcare infrastructure, substantial R&D investments, and a high prevalence of cancer. The presence of major industry players such as AbbVie Inc., Alexion Pharmaceuticals, Inc., and Amgen Inc. further reinforces the region’s leadership. Moreover, favorable regulatory support from agencies like the FDA accelerates the approval and adoption of monoclonal antibody therapies. These factors collectively ensure North America’s continued dominance in the global market, fostering innovation and growth.
Asia Pacific is expected to experience the fastest CAGR in the global market, driven by the rising incidence of cancer and increasing awareness of advanced cancer treatments. The region's rapid market expansion is also supported by growing investments in healthcare infrastructure and government initiatives to improve access to immuno-oncology therapies.
In October 2024, the Indian government launched the Biotechnology Research Innovation and Entrepreneurship Development (bio-RIDE) scheme to advance the country’s biotechnology sector, boosting the regional market’s growth prospects.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global monoclonal antibodies market is segmented into type, application, and distribution channels.
Human segment dominates the market with the largest market revenue
The human segment dominates the monoclonal antibodies market due to its superior efficacy, safety, and preventive value. Human monoclonal antibodies are developed quickly, aiding in the rapid response to health crises. Their ability to mitigate significant health and economic disruptions further bolsters their market leadership.
This innovation underscores the human segment’s dominance, driven by its ability to provide effective and timely solutions.
Oncology segment dominates the market with the largest market revenue
The oncology segment leads the global market due to the rising global prevalence of cancer and the increased focus of market players on developing targeted cancer therapies. This has resulted in a robust pipeline of monoclonal antibodies for oncology. According to the American Cancer Society, 20 million new cancer cases were reported globally in 2022, with projections reaching 35 million by 2050. The escalating need for effective cancer treatments ensures the oncology segment remains the dominant application, driving continued investment and innovation in monoclonal antibody therapies.
Hospital pharmacies segment dominates the market with the largest market revenue
Hospital pharmacies dominate the market due to their essential role in the integrated care and treatment of critical conditions like cancer and autoimmune diseases. Monoclonal antibodies often require specialized administration in hospital settings, where hospital pharmacies provide superior support compared to other channels. Their direct connection with hospitals ensures patient-centric care, which is crucial for life-threatening conditions. This critical function makes hospital pharmacies the leading distribution channel, as they cater effectively to the specialized needs of patients requiring monoclonal antibody treatments.
Key players in the global market are actively pursuing strategic collaborations, acquisitions, and partnerships to enhance their product offerings and broaden their market reach. These strategies enable companies to leverage complementary strengths, access new technologies, and enter emerging markets.
Fortis Life Sciences: An emerging provider in the global Monoclonal Antibodies Market
Fortis Life Sciences is an emerging player recognized for its innovative antibodies and antisera products, antigen proteins, assays, and kits, positioning the company as a key player in advancing biologics. The company’s commitment to research and development has led to the creation of high-quality, customizable solutions catering to diverse therapeutic needs.
Recent Development:
In May 2023, Fortis Life Sciences announced a strategic partnership with Lunaphore and Bethyl Laboratories to leverage its extensive library of primary antibodies on the COMET platform, aimed at expanding spatial biology services. This collaboration enhances Fortis's capability to offer advanced spatial biology solutions, facilitating precise and comprehensive analysis of tissue samples.
As per our analyst, the global market is experiencing rapid expansion, driven by a variety of key factors. The rising prevalence of life-threatening diseases, such as cancer, autoimmune disorders, and infectious diseases, coupled with the increasing need for monoclonal antibodies as effective treatment options, is propelling market demand.
Moreover, advancements in biotechnology, the growing focus on personalized medicine, and the expanding pipeline of monoclonal antibody-based therapies are contributing to the market's robust growth. However, challenges like the high cost of monoclonal antibody therapies remain a significant barrier, limiting access to treatment for patients, especially in emerging markets.
The complexity of manufacturing monoclonal antibodies, along with regulatory hurdles and intellectual property concerns, poses risks to market expansion. Despite these challenges, the continued advancements in research and the increasing acceptance of monoclonal antibodies in clinical settings are expected to fuel future growth.
